Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMUSLW3)

Drug Name

Carbetocin Drug Info

Synonyms

Carbetocino [INN-Spanish]; Carbetocinum [INN-Latin]; Duratocin (TN); 1-Buttersaeure-2-(3-(4-methoxyphenyl)-L-alanin)oxytocin; 1-{[(3r,6s,9s,12s,15s)-6-(2-amino-2-oxoethyl)-9-(3-amino-3-oxopropyl)-12-[(2s)-butan-2-yl]-15-(4-hydroxybenzyl)-16-methyl-5,8,11,14,17-pentaoxo-1-thia-4,7,10,13,16-pentaazacycloicosan-3-yl]carbonyl}-l-prolyl-l-leucylglycinamide

Indication

Disease Entry	ICD 11	Status	REF
Postpartum haemorrhage	JA43	Approved	[1]

Therapeutic Class

Antitocolytic Agents

Cross-matching ID

PubChem CID: 16681432
ChEBI ID: CHEBI:59204
CAS Number: CAS 37025-55-1
TTD Drug ID: DMUSLW3

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Patented Agent(s)

Download the Complete Related Drug List

Drug(s) Targeting Oxytocin receptor (OTR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Desmopressin	DMS3GVE	Diabetic complication	5A2Y	Approved	[3]
Oxytocin	DMDL27I	Autism spectrum disorder	6A02	Approved	[4]
ATOSIBAN	DMB7WYM	N. A.	N. A.	Phase 4	[5]
Retosiban	DMOYGZF	Preterm labour	JB00	Phase 3	[6]
SSR149415	DMCMD93	Anxiety disorder	6B00-6B0Z	Phase 2	[7]
Barusiban	DMWI0X3	Androgen deficiency	5A81.1	Phase 2	[8]
FE-202767	DMDGZ1C	Erectile dysfunction	HA01.1	Phase 2	[4]
GSK-557296	DM3ZL2O	Premature ejaculation	HA03.0Z	Phase 2	[9]
Pyrrolidine derivative 13	DM3VA8P	N. A.	N. A.	Patented	[10]
PMID28906174-Compound-figure1g	DMECU90	N. A.	N. A.	Patented	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Oxytocin receptor (OTR)	TTSCIUP	OXYR_HUMAN	Agonist	[2]

------------------------------------------------------------------------------------

References

1	Clinical Textbook of Dental Hygiene and Therapy. 2006, P237. By Robert Ireland.
2	Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents. Prog Brain Res. 2008;170:473-512.
3	Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4. J Med Chem. 2004 Apr 22;47(9):2375-88.
4	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 369).
5	Pyridobenzodiazepines: a novel class of orally active, vasopressin V2 receptor selective agonists. Bioorg Med Chem Lett. 2006 Feb 15;16(4):954-9.
6	The Effect of an Oxytocin Receptor Antagonist (Retosiban, GSK221149A) on the Response of Human Myometrial Explants to Prolonged Mechanical Stretch.Endocrinology.2015 Oct;156(10):3511-6.
7	Tetrahydroquinoline sulfonamides as vasopressin 1b receptor antagonists. Bioorg Med Chem Lett. 2009 Nov 1;19(21):6018-22.
8	The effect of barusiban, a selective oxytocin antagonist, in threatened preterm labor at late gestational age: a randomized, double-blind, placebo-controlled trial. Am J Obstet Gynecol. 2009 Jun;200(6):627.e1-10.
9	Inhibition of ejaculation by the non-peptide oxytocin receptor antagonist GSK557296: a multi-level site of action. Br J Pharmacol. 2013 Aug;169(7):1477-85.
10	A patent review of oxytocin receptor antagonists 2013-2017.Expert Opin Ther Pat. 2017 Dec;27(12):1287-1290.